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DEFINING THE ROLE OF THE GUT MICROBIOME IN COLORECTAL 





 Colorectal cancer (CRC) has the 3rd highest incidence and 2nd highest mortality of 
all cancers in the United States. These numbers have improved with proper screening and 
the development of new therapies, but CRC continues to evade detection and resist 
therapy in late stages. The gut microbiome has emerged as a possible explanation for 
heterogeneity in this disease. In order to help develop screening techniques and accurate, 
targeted therapies, this review covers the molecular mechanisms by which the 
microbiome induces CRC. An analysis of current research has confirmed its 
physiological roles of maintaining intestinal immune homeostasis and metabolizing 
products produced by the host. When these functions are impaired, CRC can develop. 
This may occur through damage to the intestinal barrier, inflammation, and production of 
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 The finding that colorectal cancer (CRC) progresses through a predictable 
adenoma-carcinoma sequence has significantly lowered its incidence and mortality. CRC 
begins with a dysplastic polyp, or adenoma, which proceeds to carcinoma when certain 
genetic mutations are acquired. Because of this, it is recommended that any polyps found 
during screening are surgically removed and followed up periodically to screen for 
additional polyps. Of cases that bypass detection and progress to carcinoma, the 
development of chemotherapies like 5-fluoruracil (5-FU) and combination therapies that 
utilize radiology, immunotherapy, and targeted therapies have improved the prognosis of 
CRC at early stages. However, even with these advances, CRC remains the 3rd most 
common cancer with the 2nd highest rate of mortality in the United States, with mortality 
increasing along with stage. Consequently, it is of great importance to develop accurate 
screening techniques and therapies that are less invasive and cost less than what is 
currently available. 
 Along with the adenoma-carcinoma sequence, the gut microbiome has emerged as 
an active contributor to colorectal carcinogenesis. Numerous studies have found specific 
microbiome configurations and bacterial species associated with the presentation of CRC 
in both tissue and stool samples and at various CRC stages. The role of the gut 
microbiome in physiological processes like immune homeostasis and host metabolism 
further support its potentially pathogenic role in carcinogenesis. At the same time, the 
microbiome has shown potential as a prognostic and therapeutic tool. Several studies 
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have identified biomarkers derived from the microbiome that predict CRC incidence, and 
studies of its pathogenic mechanisms have identified points of intervention. The use of 
fecal microbiota transplantation (FMT) in recurrent Clostridium difficile infections is one 
example of this. The role of the microbiome as a causative agent in CRC, however, has 
yet to be established, with some arguing that the changes in cellular activity are merely an 
effect of host processes. This discussion has been complicated by variations in gut 
microbiome structure, complex relationships, and vague terminology. Furthermore, few 
reviews exist that compare physiological function to pathological mechanisms. Doing so 




 The aim of this review is to assess the causative role of the gut microbiome in 
colorectal carcinogenesis. This will be done by first reviewing the molecular mechanisms 
of colorectal cancer and cancer in general. Topics such as cancer hallmarks, driver and 
passenger mutations, and Wnt-β-catenin and RAS-RAF pathways will provide a 
framework to understand the potential mechanism of action of the microbiome in 
carcinogenesis. An overview of the human microbiome—and gut microbiome—
terminology, development, and structure will be provided so that a physiological state can 
be compared to pathological states. Variation in microbiome structure will be discussed 
as an argument is made for what constitutes a healthy gut microbiome. Special attention 
will be given to the physiological roles of the gut microbiome, as these functions have 
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been implicated in microbiome-mediated carcinogenesis; these will include host immune 
system modulation and modulation of host metabolism. Metabolism will be discussed as 
its pathogenic potential is discussed. Theories such as “dysbiosis” and “bacterial drivers” 
will be presented as a potential lens to understand the mechanisms by which the 
microbiome induces CRC. The mechanisms of an impaired intestinal barrier, 
inflammation, genotoxin production, and altered metabolism will be presented as 
potential causes of CRC progression. These topics will focus on the molecular processes 






 Genetic material, in fragments or by genome, can now be sequenced in less time, 
at lower costs, and with greater accuracy than ever before. For example, the Human 
Genome Project took over 13 years and $2.7 billion dollars to sequence the human 
genome by 2003, whereas an individual’s genome can now be sequenced in almost a day 
and for less than $1000 (Gautam et al., 2019; Wetterstrand, 2019). These advances have 
led to the identification of genetic lesions that drive disease, the mechanisms by which 
genetic disorders advance, and targets for therapy. This is especially true for cancer, 
primarily a genetic disease. Over 300 cancer genes have been identified by the Cancer 
Genome Atlas Program. Many cellular pathways like the Wnt and RAS-RAF pathways 
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have been elucidated, and treatments have targeted various steps along the carcinogenic 
sequence (Bailey et al., 2018; Haber & Settleman, 2007).  
 In the simplest of terms, cancer is the accumulation of genetic mutations that lead 
to excessive growth and, eventually, tissue damage and migration to distant sites, or 
metastasis (Iranzo et al., 2018). These genetic lesions vary in size, affecting single 
nucleotides or large sections of chromosomes, and commonly affect cell cycle 
checkpoints. The genes that they affect are termed ‘cancer genes’ and can be classified as 
oncogenes, tumor suppressor genes, apoptosis genes or genes of the tumor 
microenvironment, depending on what effect they have on cancerous tissue (Iranzo et al., 
2018; Kumar et al., 2018). They also have multiple etiologies. They have been classically 
divided as either inherited, germline mutations, or spontaneous, somatic mutations, but 
epigenetic processes are now included in this division (You & Jones, 2012). DNA 
methylation, histone modification, nucleosome alterations, microRNA (miRNA) all fall 
within this category (Zhai et al., 2017). Regardless of the type of mutation, the process is 
the same; alterations in the expression of key regulatory genes lead to cellular 
proliferation and ultimately metastasis.  
 Carcinogenesis proceeds in three stages: initiation, promotion, and progression. 
Initiation begins with 1-5 driver mutations that permit the division of a single cell (Iranzo 
et al., 2018; Tomasetti et al., 2015). These mutations vary by cancer type in both identity 
and number. Promotion alters the expression of the genome without changing that actual 
genetic structure so that the cell can undergo clonal expansion (Pitot, 1993). Genetic 
alterations are passed along to each generation of daughter cells, and their survival is 
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dictated by Darwinian selection (Nunes, 2020). Those that are better adapted to the tumor 
microenvironment form the dominant population, while those that are not form auxiliary 
populations, or subclones (Nunes, 2020). Progression is defined by the continued 
accumulation of mutations or genetic changes that significantly alter the rate of division 
or metastatic ability (Arvelo et al., 2016). It is during this stage that cancers are given 
phenotypes and are staged.   
 The results of cancerous mutations have been classically defined as the hallmarks 
of cancer. These include: sustaining proliferative signaling, evading growth suppressors, 
resisting cell death, enabling replicative immortality, inducing angiogenesis, activating 
invasion and metastasis, reprogramming energy metabolism, and evading immune 
destruction (Edwardson et al., 2019; Hanahan & Weinberg, 2011; Pavlova & Thompson, 
2016). Genetic instability and inflammation are closely related, but primarily serve to 
increase the rate of cancer progression. For example, microsatellite instability is 
characterized by sections of highly repetitive DNA that are prone to mutation (Morganti 
et al., 2019). The role of inflammation is best seen in the increased risk of CRC with the 
diagnosis of inflammatory bowel disease (IBD) (Axelrad et al., 2016). In this example, 
mutations of p53 and APC are commonly observed and are likely due to the release of 
reactive oxygen species (ROS) by host immune cells (Axelrad et al., 2016). As time 
progresses, cancerous tissue continues to acquire new abilities, making its treatment 
increasingly difficult.  
 Researchers have also adopted the terms ‘driver mutation’ and ‘passenger 
mutation’ to better identify which cancer genes significantly contribute to cancer 
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progression. Driver mutations are said to directly alter cancer genes and contribute to the 
overall fitness of cancer cells (Bozic et al., 2010). On the other hand, passenger mutations 
are those that occur coincidentally and do not contribute to the selective growth 
advantage of cancer cells—though there is some evidence that passenger mutations may 
also contribute to cancer heterogeneity (Kumar et al., 2018; McFarland et al., 2017). This 
distinction is important because cancers accumulate mutations along their entire lifetime 
and will have hundreds of driver mutations by the time of diagnosis (Diaz et al., 2012). 
This large number increases the fitness of a tumor and enables its resistance to treatment. 
Identification of driver mutations can then be used to develop biomarkers for earlier 
diagnosis or improved prognosis.   
 In addition to genetic factors, it is becoming increasingly apparent that 
environmental factors play a role in tumorigenesis. This is best seen in the geographical 
distribution of cancer incidence and mortality. For example, the incidence of colorectal 
cancer is about twice as high for African Americans as it is for rural South Africans, an 
observation that has been attributed to a difference in diet (O’Keefe et al., 2015). Other 
notable environmental factors include smoking, alcohol consumption, sun exposure, and 
reproductive history (Song & Chan, 2019). These factors have been identified primarily 
through their consistent associations with cancer but also through the finding of specific 
carcinogens. These molecules either directly damage DNA, like aflatoxin, or disrupt the 
regulation of cellular proliferation, like estrogen (Kumar et al., 2018). CRC is one cancer 





 CRC, or adenocarcinoma, is a cancer that affects glandular epithelial tissue. It is a 
slow growing tumor that follows a predictable adenoma-carcinoma sequence (Leslie et 
al., 2002). Over the course of about 10 years, it begins with a collection of genetic lesions 
that lead to abnormal growth, proceeds through phases of hyperplasia and dysplasia, 
organizes as a benign adenomatous polyp (adenoma), and acquires malignancy with its 
damage to tissue and invasion of adjacent tissue (Rawla et al., 2019). Only 10% of polyps 
proceed to cancer, but their risk of developing malignancy increases with size and age. 
There is no consistent indicator of which polyps will become cancerous, so it is critical to 
identify and remove polyps before they develop malignancy. Screening typically begins 
at age 50 and utilizes techniques such as colonoscopy and fecal immunochemical testing 
(FIT). If polyps are identified, they are removed and followed up every 4-7 years (Leslie 
et al., 2002; Patel & Ahnen, 2015). This strategy has lowered the incidence of CRC, but a 
third of patients fail to follow screening recommendations, the incidence of CRC is rising 
in younger adults, and some polyps evade detection (Baxter et al., 2016; Siegel et al., 
2020). For example, it is estimated that FIT only detects 7.6% of non-advanced adenomas 
(Baxter et al., 2016). 
The importance of early CRC detection is also seen in its staging. If CRC is 
diagnosed early, at Stages I and II, it has a five-year relative survival rate of about 90% 
(Rawla et al., 2019). However, by stage IV, patients experience multiple cases of 
recurrence, and only 12% survive beyond five years (Rawla et al., 2019). This effectively 
leads to an annual 50,000 deaths in the US and the ranking of CRC as the second highest 
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cause of cancer mortality. This has not only promoted the importance of early detection, 
but also the development of more effective therapies. This has been addressed by a 
combination of surgery, chemotherapy, radiotherapy, immunotherapy, and targeted 
therapies. 5-flourouracil (5-FU) has become a mainstay as a chemotherapy agent, but 
advanced tumors have adapted to this; almost half of metastatic CRCs are resistant to 5-
FU (Van der Jeught et al., 2018). Similar resistances are seen in radiotherapy, 
immunotherapy, targeted therapy, and surgery (Zhai et al., 2017; Zhu et al., 2018). Part of 
this heterogeneity can be explained by the variety of etiologies and genetic lesions found 
within CRC. 
CRC ETIOLOGY 
 CRC is a multifactorial disease defined by a combination of genetic and 
environmental factors, with one’s environment having an increasingly significant role. It 
is estimated that the incidence of 50-60% of CRC could be prevented by lifestyle 
modifications alone (Song & Chan, 2019). As with most cancers, factors like smoking, 
alcohol, poor hygiene, sedentary lifestyles, and high body fat content are associated with 
increased incidences of CRC (Rawla et al., 2019). One’s diet has also been associated 
with select cancers but is especially apparent in CRC. Diets identified by high fat and red 
meat content are associated with increased risks, whereas those with fiber, complex 
carbohydrates, whole grains, omega-3 fatty acids, and Vitamin D are associated with 
lower risks (O’Keefe et al., 2015). For this reason, it has been explained that Western 
diets carry a high risk of CRC, whereas balanced diets, those that include fruits, 
vegetables, and high fiber content, are associated with a low risk of CRC. This is one 
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explanation  why the rate of CRC incidence has increased in countries, like Japan, as they 
have adopted Western cultures (Song & Chan, 2019).   
 Fearon and Vogelstein first identified CRC driver mutations as those that affect 
tumor suppressor genes (such as adenomatous polyposis coli (APC), TP53 and SMAD 
family member 4 (SMAD4)) and oncogenes (such as KRAS and PI3K catalytic subunit‑α 
(PIK3CA)) (Fearon & Vogelstein, 1990). It has now been observed that these mutations 
affect either the Wnt-β-catenin pathway or the RAS-ERK pathway (the serrated polyp 
neoplasia pathway) (Dienstmann et al., 2017). About 80% of adenocarcinomas arise from 
the Wnt-β-catenin pathway and 20% arise from the RAS-ERK pathway (Figure 1). APC 
was originally identified in patients with familial adenomatous polyposis (FAP), who 
present with hundreds to thousands of polyps in childhood or early adulthood (Kumar et 
al., 2018). This gene encodes for a large, multicomplex protein that is known for its 
regulation of β-catenin, a component of the Wnt signaling pathway. Wnt activates β-
catenin, whereas APC targets it for degradation through the ubiquitin-proteosome 
pathway. Once activated, β-catenin serves as an activator of the transcription factors 
lymphoid enhancer factor (LEF) and T cell factor (TCF) (Rubinstein et al., 2013). These 
factors have been associated with the expression of NF-kB, Wnt, and the activation of 
oncogenes Myc and cyclin D1, a response that is collectively referred to as β-catenin 
related transcription, or CRT. It is important to note that Wnt and β-catenin are also prone 
to mutation in this classification but occur less frequently than mutations in APC. CRCs 
that proceed through the RAS-RAF pathway commonly include mutations in BRAF or 
KRAS (Rodriguez-Salas et al., 2017). Activation of the GTPase Ras activates the RAF-
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MEK-ERK phosphorylation pathway (Figure 2). Phosphorylated ERK translocates to the 
nucleus, activates transcription factors like ATF, and ultimately stimulates cellular 
processes, such as the proliferation of cells (Jeong et al., 2018). Even with improvements 
in molecular classification, CRC displays significant heterogeneity. The role of the 
microbiome has emerged as one possible explanation.  
 
 
Figure 1. Wnt-β-catenin Pathway. Without Wnt, APC targets β-catenin for degredation 
through the ubiquitin-proteasome pathway. With Wnt binding, β-catenin translocates to 
the nucleus and activates the transcription factors TCF/LEF which leads to cellular 
proliferation through the action of NF-kB, Wnt, Myc and cyclin D1. Taken from (Jeong 





Figure 2. RAS-RAF Pathway. Activation of the RAS-RAF pathway normally occurs 
through the binding of receptor tyrosine kinases (RTKs) like epidermal growth factor 
receptor (EGFR) and proceeds through stepwise phosphorylations. Ras and Raf are 
commonly mutated in CRC and lead to cellular processes like proliferation of cells. 
Taken from (Jeong et al., 2018) 
 
 
THE HUMAN MICROBIOME  
The microbiome is the ecosystem that contains all of the microorganisms living 
within a host and their genetic material (Watson et al., 2020). ‘Microbiota’ is similar to 
this but refers exclusively to the microorganisms and not their genomes. Most of research 
is focused on the ‘microbiome’ because the genome is used for taxonomical classification 
and mediates the effects of microorganisms on their host. Microbiota is typically used 
when referring to the actions of specific commensal or pathogenic microorganisms. In 
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practice, these terms are used interchangeably, but this review will use the two 
purposefully for the sake of consistency within the literature.   
TAXONOMY 
There are eight taxonomical ranks that increase in specificity. From largest to 
smallest, these include Domain, Kingdom, Phylum, Class, Order, Family, Genus, and 
Species (Table 1) (Watson et al., 2020). Domains of life are not addressed in research 
very often, but the six kingdoms are. These include Animalia, Plantae, Fungi, Protista, 
Archae, and Bacteria. Bacteria are usually given the most attention because of their vast 
numbers, but other kingdoms also play significant roles in the health of their host. For 
example, candida albicans, a species of Fungi, is normally found on the skin and in 
locations like the mouth, gut, and vagina (Gow & Yadav, 2017). When its numbers are 
abnormally elevated, it can lead to infection, such as vaginal candidiasis. Viruses, though 
they are not alive and technically do not belong to any of these domains, are also active 
members of the human microbiome. Their significance is seen in the association of 
neonatal malnourishment with abnormal virome development (Zmora et al., 2019).  
Table 1. Taxonomy of the Gut Microbiome. Taken from (Watson et al., 2020) 
 
 
In early taxonomy, microbes were divided into classes by morphology. This 
method was beneficial because it provided researchers with a common language to 
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identify specific species. For example, bacteriophages were classified as A (having 
contractile tails), B (long noncontractile tails), and C (short noncontractile tails) (Tolstoy 
et al., 2018). Morphology is still used in classifications today, but is limited in its use in 
making inferences about function (Parks et al., 2018). All Actinobacteria, a major 
bacteria phylum, may be gram-positive, but some are commensal while others are 
pathogenic (Barka et al., 2015). Microbes with shared structures may appear similar but 
differ in their effects on a host. This limitation is partially due to the genomes that 
mediate the actions of microbes. 
With the advances in genetic sequencing, researchers gained the ability to classify 
microbes by their evolutionary development instead of morphology. This method based 
its taxa on similarities in genetic sequences instead of exclusively morphology (Tolstoy et 
al., 2018). Those that shared a greater percentage of sequences were inferred to be more 
closely related and to possess similar functions. The plasticity, or recombination, of 
microbial genomes, a major difference from the genomes of humans, hindered this 
method of classification at the start, but was overcome with the use of more advanced 
sequencing techniques like the use of sub-OTUs (operational taxonomic units) or 
amplicon sequence variants (Tolstoy et al., 2018; Watson et al., 2020; Zmora et al., 
2019). Now, microorganisms are largely categorized by their genome and inferences in 
microbe function have improved.  
The significance of taxonomy in microbiome research is seen in the 
inconsistencies in reported data and conclusions. One study may identify the composition 
of the gut microbiome at the level of phylum (Firmicutes and Bacteriodetes), whereas 
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another may report at the level of species and omit phyla (Lloyd-Price et al., 2017; 
Sommer & Bäckhed, 2013). In these cases, the data often do not contradict and only 
differ by what level of taxa are reported. Furthermore, even small variations in a 
microbe’s genome affect its clinical significance. For example, one strain of Fusbactium 
nucleatum (Fn), CTI-2, expresses the surface protein Fap2, but CTI-7 does not (Abed et 
al., 2016). It turns out that this difference in protein expression, even at the strain level, 
has significant implications in regards to its virulence. Because of this, some researchers 
have suggested that only studies that report at the subspecies level can be used to 
establish causation (Brüssow, 2019). However, the consensus seems to be that the species 
level is sufficient for translating research into clinical practice.  
NICHE SPECIFICITY 
The microbiome also differs by anatomical location, a concept that has been 
termed ‘niche specificity’ (Zmora et al., 2019). The oral and gut microbiomes have been 
shown to have prominent physiological roles and are studied the most. This review will 
focus on the gut microbiome, but it is important to note that there are other anatomical 
sites, such as the bladder and vagina, that harbor significant numbers of microorganisms. 
The key to understanding this site-specific distribution is explained by the field of 
ecology. The microbiome is a complex ecosystem with multiple factors that determine a 
species survival. In the case of the human microbiome, oxygen content, pH, nutrient 
availability, and temperature play significant roles (Durack & Lynch, 2018).  Because of 
this, it is theorized that the microbiota evolved in the gut because of its consistent 
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temperature and supply of nutrients. The arrangement of a specific niche is dependent 
upon the characteristics of that environment.  
At the same time, the structure of a microbial niche is dependent upon the 
genomes of the very microorganisms that comprise it. Like the Darwinian forces that 
govern clonal expansion in cancer, species that possess favorable genes will adapt to their 
environment and outnumber their competitors. In contrast, those that are unable to adapt 
will decrease in number—a concept described as competitive colonization (Stecher, 
2015). This is best seen in the arrangement of the gut microbiota with respect to the 
lumen and the mucus layer of the gut. The lumen is characterized as being high in oxygen 
content whereas the mucosa is low in oxygen content (Sommer & Bäckhed, 2013). 
Consequently, aerobic bacteria have been found to colonize the lumen and anaerobes at 
the mucosa. Competitive colonization is also seen in the expression of adhesion 
receptors, stabilization of the gut mucosal barrier, and the production of anti-microbial 
substances (Gagnière et al., 2016). What determines the makeup of an anatomical niche is 
dependent upon both the characteristics of that environment and the genomes of its 
members. When one considers the volatility of the environment, as with the introduction 
of an antibiotic, one can imagine the variation that is seen (J. G. Lee et al., 2019). From 
this point forward, any mention of the microbiome will be specific to the gut, though 
many of the principles from above can still be applied and vice versa. It also important to 
note that the gut microbiome belongs to the larger gastrointestinal microbiome, but only 




BACTERIAL ABUNDANCE AND DIVERSITY OF THE GUT MICROBIOME 
The structure of the microbiome is commonly measured by its abundance, the 
absolute number within a taxa, and alpha-diversity, the number of various taxa within a 
given environment or its richness (Watson et al., 2020). 16S rRNA sequencing is used for 
identification and quantification and whole genome shotgun (WGS) sequencing is used 
for higher detail.  It contains members of every taxonomical kingdom but includes mostly 
bacteria (Sommer & Bäckhed, 2013). There are over 100 trillion bacteria which is 10x 
greater than the number of cells that make up the human body (Cho et al., 2014). The 
abundance of microbes increases distally with the duodenum containing 103 cells per 
gram, the jejunum 104 cells per gram, the ileum 107 cells per gram, and the colon up to 
1012 cells per gram (Tjalsma et al., 2012). A greater number of bacteria is also seen in the 
lumen in comparison to the mucosa (Sommer & Bäckhed, 2013). In terms of diversity, 
500-1000 species are typically reported (Gagnière et al., 2016; Stecher, 2015). The 
distribution of bacterial diversity mirrors that of abundance with diversity increasing 
distally (Sommer & Bäckhed, 2013). 
STRUCTURAL CHANGES DURING DEVELOPMENT 
The initial colonization of the infant’s gut is thought to occur at birth (Hornef & 
Torow, 2020; Sommer & Bäckhed, 2013). As the newborn passes through the birth canal, 
the flora of the mother is passed to the infant through vertical transmission (Durack & 
Lynch, 2018). Interestingly, a difference in the organization of an individual’s 
microbiome has been observed in those birthed vaginally versus Caesarean section, 
though its significance is debated (Hornef & Torow, 2020). Further colonization is then 
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strengthened through direct contact with the mother as with breast feeding (Durack & 
Lynch, 2018). It is important to note that there is also evidence that colonization could 
begin in-utero through intra-uterine seeding, implying that the infant’s gut may not be 
sterile as is commonly thought (Ferretti et al., 2018). Regardless, the highly oxidative 
environment of the newborn favors colonization of facultative anaerobic bacteria such as 
those of the phylum Proteobacteria (Sommer & Bäckhed, 2013). These bacteria alter the 
oxygen content of the lumen so that anaerobes like those of the genus Bacteriodes and of 
the phyla Actinobacteria and Firmicutes can proliferate (Durack & Lynch, 2018; Sommer 
& Bäckhed, 2013). As an aside, the adult gut is defined by a greater number of obligate 
anaerobes than aerobes and facultative anaerobes (Sommer & Bäckhed, 2013).  
The abundance of bacteria rapidly increases and reaches adult levels during the 
first few days of life. This proliferation is possible because of the available space and a 
rich supply of lactose (Hornef & Torow, 2020) In contrast, the microbiome does not 
reach adult levels of bacterial diversity until age two or three and depends upon factors 
like geography, number of siblings, and presence of household pets (Hornef & Torow, 
2020). Even then, its composition differs from adults with lower levels of Bacteroides 
and higher levels of Bifidobacterium (Durack & Lynch, 2018). During childhood, the 
structure of the microbiome continues to change until bacteria of the phyla, Firmicutes 
and Bacteriodetes, outnumber others as in adulthood (Sommer & Bäckhed, 2013; Song & 
Chan, 2017). Adult microbiome composition displays short-term fluctuations in response 
to insults like antibiotics but maintains its structure in the long-term (Zmora et al., 2019). 
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As a general trend, richness begins to decline in the elderly and has been associated with 




WHAT IS A ‘HEALTHY’ GUT? 
 There is a consensus that a healthy adult microbiome contains mostly bacteria of 
the phyla Firmicutes (a phylum of gram-positive cocci that includes Enteroccocaceae, 
Clostridiaceae, and Ruminococcaceae) and Bacteroidetes (a phylum of gram-positive 
bacilli that includes Bacteroidaceae, Porphyromonadaceae, Prevotellaceae, 
Rikenellaceae, and Flavobacteriaceae) and lower abundances of other phyla like 
Proteobacteria (a phylum of gram-negative bacteria that includes Enterobacteriaceae, 
and Burkholderiaceae) and Actinobacteria (a phylum of gram-positive bacteria includes 
Mycobacteriaceae, Micrococcaceae, and Streptomycineae) (Kiernan et al., 2019; Watson 
et al., 2020). It is important to note that this distribution varies along the length of the 
gastrointestinal tract with the colon containing larger percentages of Bacteriodes and 
Actinobacteria (Gagnière et al., 2016) However, substantial inter-individual variability in 
diversity and abundance has been displayed at the species level. Species of the Firmicutes 
phylum may be predominate in the microbiota of one subject whereas those of the 
Actinobacteria phylum may predominate in another (Lloyd-Price et al., 2017). It was 
proposed that longitudinal prospective studies could explain these differences, but even 
these have reported inter-individual diversity (Lloyd-Price et al., 2019).  
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It may be easier to understand microbial diversity by extending the definition of 
the microbiome to include nonliving molecules as well. Doing this allows one to 
appreciate the advanced sensory functions of its members. Similar to our own cells, 
bacteria interact with their environment through processes like receptor-binding or cell 
membrane diffusion. This ability enables them to recognize neighboring cells, their 
metabolites, or other ingested molecules. This interaction then activates internal pathways 
that lead to an altered expression of various genes. For example, the recognition of small 
quorum-sensing molecules like autoinducer-2 mediates the formation of biofilms in the 
oral microbiome (Ryu et al., 2016). Fusobacterium nucleatum is a major producer of 
autoinducer-2 which is interpreted by other microbes as a measure of bacterial density 
and identity. Other significant molecules found within the gut include cytokines, 
hormones, antibodies, and antimicrobial peptides (AMPs) like polyketides. Each 
molecule has its own source and activates its own pathway. This may explain the 
correlation of microbiome structure with lifestyle factors like diet, antibiotic use, 
exercise, and hygiene (Sommer & Bäckhed, 2013).  
Despite a variance in taxonomical structure, the microbiome has shown 
consistency in its functional arrangement. This was originally shown in a 2009 study that 
measured function by the degree of enzyme expression (Lozupone et al., 2012). They 
found that the stools of 18 females shared 93% of enzymes and only a few genus-level 
phenotypes. Additional studies like the Human Microbiome Project have extended these 
findings by cross referencing species classically identified by their genome with 
measures of function (Cohen et al., 2015; Lloyd-Price et al., 2017). This project identified 
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10 ‘core pathways’ that were consistently found in the microbiomes of over 1500 
subjects. Specifically, they observed core processes like L-histidine degradation, 
peptidoglycan biosynthesis, and beta-d-glucuronide degradation. Other notable studies 
have measured function by the effects of metabolites on host cells (Kim et al., 2018; 
O’Keefe et al., 2015; Sinha et al., 2016). A variation in taxonomy but consistent function 
may seem like a paradox, but some researchers have proposed that it could be due to the 
existence of multiple stable states (Levy et al., 2017; Lozupone et al., 2012). This theory 
holds promise as the physiology of the microbiome continues to be studied, especially in 
the discussion of dysbiosis.  
MICROBIOTA-MEDIATED PHYSIOLOGY 
With over 5 million genes, the gut microbiome plays a significant role in the 
health of its host (Sommer & Bäckhed, 2013). It is because of this that some researchers 
have referred to it as its own organ (Chang & Kao, 2019; Gagnière et al., 2016). Some of 
its symbiotic relationships can be harmful to its host, but mutualistic relationships also 
exist. The microbiota benefits from a stable environment, and the host benefits from its 
expanded gene capacity. It has been associated with many host functions like organ 
development, bone growth, and behavior, but its roles in immune homeostasis and 
metabolism are the most relevant to the discussion of CRC (Durack & Lynch, 2018; 







The gut lumen contains many microbes and molecules that can cause harm to the 
host. At the same time, it contains essential nutrients and commensal microorganisms 
needed for physiological function. The intestinal immune system must, therefore, develop 
a tolerance towards beneficial materials, recognize harmful materials, and maintain a 
balance of pro-inflammatory and anti-inflammatory signals. If this is not accomplished, a 
dysfunctional immune system may lead to cases of chronic infection, hypersensitivity, or 
autoimmunity. Along with the host, the microbiome contributes to this balance by 
preventing the colonization of pathogens, promoting intestinal barrier integrity, inducing 
the development of immune cells and tissues, and modulating their function.  
The microbiome removes pathogens from the gut of its host by either directly or 
indirectly inhibiting their survival. For example, Cabellero et al. found that certain 
commensal bacteria can eliminate Vancomycin-resistant Enterococcus faecium (VRE) 
from the guts of mice (Caballero et al., 2017). Three days after the administration of a 
mixture of Clostridium cluster XIVa species Blautia producta and Clostridium bolteae, 
levels of VRE were undetectable. It was hypothesized that this occurred through the 
reduction of VRE replication or increased VRE killing specifically by B. producta. The 
use of fecal microbiota transplantation (FMT) in recurrent Clostridium difficile infections 
is an additional example of the microbiota’s protective function (Tariq et al., 2019). It is 
proposed that the competition of resources results in a remodeling of the microbiota into 
a structure without C. difficile. The exact mechanisms by which commensal bacteria 
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interfere with pathogens are not well-understood, and future studies are needed to 
develop more effective target therapies like FMT and supplemental probiotics.   
The intestinal mucosal immune system is composed of a mucus layer, a single-
cell thick lining of intestinal epithelial cells (IEC), and underlying immune cells that 
colonize the lamina propria and gut associated lymphoid tissue (GALT) (Shi et al., 2017). 
Of these, the mucus layer serves as the first line of defense and as a lubricant for passage 
of chyme and feces. It contains two layers, an inner and outer layer and is comprised of 
various types of mucins, a gel-like hyper-glycosylated protein (Chang & Kao, 2019; 
Sommer & Bäckhed, 2013). These proteins are secreted by Goblet cells with mucin 2 
(MUC2) being the major form. They are arranged in sheet-like layers with pores smaller 
than most microbes. This structure protects the host by preventing the passage of 
materials according to size and charge (Li et al., 2013). The importance of the 
microbiome is seen in the increasing thickness of mucus as the density of microbes 
increases, with the thickest portion residing in the colon (Muniz et al., 2012). The 
microbiome maintains the mucus layer by regulating Goblet cell development and mucin 
production (Sicard et al., 2017). For example, it has been shown that B. thetaiotaomicron 
increases Goblet cell differentiation and expression of mucus-related genes, Lactobacillus 
species stimulate MUC2 production, and bacterial metabolites like short chain fatty acids 
(SCFA) support the production of MUC2 (Sicard et al., 2017). These studies support the 
finding of thin mucus layers, few Goblet cells, and altered mucin charges in germ free 
mice compared to conventionally raised mice (Sommer & Bäckhed, 2013). They also 
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provide a potential mechanism by which Bifidobacterium longum restores mucus 
production in mice fed Western style diets (Schroeder et al., 2018).  
The IEC includes five types of cells: mucus-producing goblet cells, AMP-
producing Paneth cells, hormone-producing enteroendocrine cells, antigen-presenting 
microfold (M) cells, and nutrient-absorbing enterocytes (Figure 3) (Muniz et al., 2012). 
Molecules can cross this lining through a transcellular pathway (across cell membranes) 
or a paracellular pathway (between cells). Tight junctions (TJ), protein complexes made 
of occludins, claudins, and zonula occludins, protect the host by regulating paracellular 
passage (Chelakkot et al., 2018). It must be permeable enough to allow for the passage of 
some ions and nutrients, but also tight enough to prevent the passage of proteins, lipids, 
and microbial metabolites. Several studies have shown that the microbiome is integral in 
maintaining TJ integrity (Bansal et al., 2010; Pruteanu & Shanahan, 2013; Y. Zhang et 
al., 2018). For example, germ free (GF) mice are at great risk of developing colitis and 
inflammatory bowel disease, and administration of probiotic mixtures can reduce 
inflammation of the intestines (Sommer & Bäckhed, 2013; Y. Zhang et al., 2018). 
Interestingly, some commensals have been shown to decrease TJ permeability by 
promoting TJ protein expression, while others produce proteases that increase TJ 
permeability (Chang & Kao, 2019). This may be caused directly through PRR activation 
as seen by a reduced permeability with Lactobactillus activation of TLR-2 signaling or 
indirectly through the production of cytokines (Chelakkot et al., 2018; Ganal‐Vonarburg 
& Duerr, 2020; Sommer & Bäckhed, 2013). Some bacteria may also increase 
permeability through the production of Tumor necrosis factor-α (TNF-α) and interferon-γ 
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(IFNγ), though the method by which this occur is not well-understood (Chelakkot et al., 
2018; Muniz et al., 2012).  
 
 
Figure 3: Intestinal Immune Barrier. The intestinal immune barrier is composed of a 
mucus layer, an intestinal epithelial cell (IEC) layer, and immune cells that reside in the 
lamina propria and secondary lymphoid organs (SLOs). The commensal bacteria and host 
immune system shape one another through the action of metabolites and receptor-ligand 
activation of intracellular pathways. Taken from (Muniz et al., 2012). 
 
IECs also express pattern recognition receptors (PRRs) like toll-like receptors 
(TLRs) and NOD-like receptors (NLRs). These receptors have many functions but are 
critical in the production of protective substances like antimicrobial peptides (AMPs) and 
IgA in response to microbial-associated molecular patterns (MAMPs) (Thaiss et al., 
2016). AMPs belong to a diverse class of proteins and include defensins, cathelicidins, C-
type lectins, intestinal enzymes, and S100 proteins (Muniz et al., 2012). They belong to 
the innate immune system and protect the host by directly neutralizing microbes and 









example, LL-37, a cathelicidin, binds to microbes through electrostatic attractions and 
causes the formation of pores in their membrane, and HBD3, a β-defensin, interacts with 
dendritic cells and macrophages through TLR1 and TLR2 and alters the expression of 
surface molecules (Muniz et al., 2012). They are produced by many IECs but mostly by 
Paneth cells and enterocytes to a lesser extent. Moreover, some are expressed 
constitutively, as with α-defensins and β-defensin 1, while others are only produced in 
response to the binding of microbes (Sommer & Bäckhed, 2013). This relationship was 
first established through the finding of fewer AMPs in GF mice, and then strengthened by 
the identification of specific bacteria that could induce their production (Muniz et al., 
2012). It was later concluded that commensal bacteria and pathogens regulated AMP 
production through an MyD88-dependent NF-κB pathway (Muniz et al., 2012; L. Zhang 
& Gallo, 2016).  
 IgA has many functions within the gut. It is needed to colonize mucosal bacteria, 
induce bacterial adaptations, and protect the host by blocking microbial activity and 
increasing their clearance (Chang & Kao, 2019; Hoces et al., 2020). Plasma cells, or 
differentiated B cells, are needed for IgA production and reside within intestinal 
lymphoid structures, such as Peyer’s Patches (PP) and isolated lymphoid follicles (ILFs) 
(Buettner & Lochner, 2016). Once secreted, IgA is transcytosed across IECs and interacts 
with commensal and pathogenic bacteria in the mucus layer and lumen (Sommer & 
Bäckhed, 2013). Most of research has focused on its role in shaping the microbiota, but 
the microbiota also promotes IgA production. As with AMP, fewer IgA, fewer ILFs, and 
immature PP were observed in GF mice compared to conventionally raised mice 
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(Sommer & Bäckhed, 2013). Several studies have shown that a variety of commensals, 
especially those that belong to the Proteobacteria phylum, induce the formation of IgA 
during development and steady-states (Durack & Lynch, 2018; Wilmore et al., 2018; C. 
Yang et al., 2020). Most research indicates that this occurs through a T-cell dependent 
pathway, though STING-dependent (stimulator of interferon genes) stimulation of innate 
lymphoid cells (ILCs) and flagellin-activation of dendritic cells are alternative 
mechanisms (Canesso et al., 2018; Ganal‐Vonarburg & Duerr, 2020; Melo-Gonzalez et 
al., 2019; Sommer & Bäckhed, 2013; C. Yang et al., 2020).  
The intestinal mucosal immune cells protect the host by generating inflammation 
and neutralizing pathogens, while at the same time tolerating commensal 
microorganisms. Macrophages, dendritic cells (DCs), B cells, plasma cells, T cells 
(especially CD4+ T helper cells (Th) and regulatory T cells (Tregs)), and innate lymphoid 
cells (ILCs) mediate this function in the small and large intestines (Muniz et al., 2012; 
Thaiss et al., 2016). Macrophages and DCs induce proinflammatory Th17 cells and the 
anti-inflammatory action of Tregs. Macrophages are largely classified as anti-
inflammatory and kill microbes by phagocytosis, and DCs are largely proinflammatory. 
DCs are especially important in the maturation of lymphocytes due to their ability to 
sense luminal contents and present antigens to GALT (Shi et al., 2017). These immune 
cells are distributed throughout the intestinal mucosa and are concentrated in GALT 
including Peyer’s Patches, isolated lymphoid follicles (ILFs), and mesenteric lymph 
nodes (mLNs) as seen in Figure 4 (Buettner & Lochner, 2016; Muniz et al., 2012). In 
addition to host genetics and other environmental factors, the initial development, 
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postnatal maturation, and maintenance of GALT is promoted by several commensal 
species and their metabolites as evidenced by the underdevelopment of GALT in GF 
mice (Hornef & Torow, 2020; Muniz et al., 2012; Shi et al., 2017; Sommer & Bäckhed, 
2013). For example, peptidoglycan, a gram-negative bacterial metabolite, has been shown 
to be sufficient to induce the formation of ILFs in GF mice (Sommer & Bäckhed, 2013). 
The microbiome also contributes to the modulation of intestinal immune cell activity by 
altering transcription, epigenetic programming, and hierarchical feedback loops (Thaiss 
et al., 2016). This can be through the binding of PRRs expressed on IEC’s or the immune 
cells themselves by microbe adhesins or secreted metabolites (Shi et al., 2017; Thaiss et 
al., 2016). Often times, binding of these receptors changes the expression of 
proinflammatory and anti-inflammatory cytokines. For example, polysaccharide A, a 
Bacteriodes fragilis metabolite, induces the formation of Foxp3+ Treg cells, which 
produce anti-inflammatory IL-10, through TLR2 (Shi et al., 2017). The significance of 
the microbiome in maintaining intestinal immune homeostasis is seen in the increased 




Figure 4. Secondary Lymphoid Organs of the Small Intestine. Host immune cells 
localize in the intestine at Gut Associated Lymphoid Tissue (GALT). These structures 
include Innate Lymphoid Follicles and Peyer’s Patches in the small intestine. ILFs 
develop first as cryptopatches and then immature ILFs and finish as mature ILFs. Peyer’s 
Patches have distinct morphologies with high densities of T-lymphocytes. These 
structures are unique to the small intestine, but the colon contains similar structures with 




MICROBIOME-MEDIATED COLORECTAL CARCINOGENESIS 
 The microbiome has been associated with a range of disorders such as IBD, 
diabetes, non-alcoholic fatty liver disease, asthma, and autism (Durack & Lynch, 2018; 
Jayakumar & Loomba, 2019; Petersen & Round, 2014). It was first hypothesized that 
certain residents of the gastrointestinal tract may promote carcinogenesis with the 
observation that 20% of cancers are infectious in nature (C. Yang et al., 2020). The 
observed association of microbes like human papilloma virus (HPV) and Helicobacter 
pylori (H. pylori) with cervical cancer and gastric cancer, respectively, also strengthened 
this hypothesis (Watson et al., 2020). It was then hypothesized that the microbiome may 
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induce CRC through a series of studies that utilize statistical analyses, in vitro 
experimentation, GF mice, and human biopsies. These studies found three major 
observations; 1) CRC incidence varies with geography and diet, two major determinants 
of microbiome structure, 2) GF mice display lower incidences of CRC than 
conventionally raised mice, and 3) specific gut microbiome structures and species are 
consistently associated with in CRC fecal and tissue samples (Gagnière et al., 2016; Song 
& Chan, 2019). Since then, the identification of specific virulence factors and metabolites 
with therapeutic potential have supported the role of the microbiome in colorectal 
carcinogenesis (Kim et al., 2018; Rubinstein et al., 2013; Sinha et al., 2016). One 
complexity has been the intertwined relationship of the microbe-host-diet axis. The 
structure and function of the microbiome and host are both dependent upon one another, 
but can be differentiated using proper study designs (Chang & Kao, 2019; Neville et al., 
2018). The role of the diet has been extensively reviewed elsewhere and will not be 
covered (O’Keefe, 2016; Song & Chan, 2017; Zmora et al., 2019).  
 Two theories have been presented to explain when and how the microbiome may 
initiate or promote CRC. These include 1) dysbiosis, the taxonomical and functional 
arrangement of the gut microbiota identified by a loss of commensals or growth of 
pathogens and the development of pro-carcinogenic features and 2) ‘bacterial drivers’, 
specific species that alter host genetics and lead to the acquisition of cancer hallmarks 
(Gagnière et al., 2016; Levy et al., 2017; Petersen & Round, 2014). The theory of 
dysbiosis has been critiqued because some researchers’ only define dysbiosis as an 
alteration of community structure and do not report at the species level (Brüssow, 2019; 
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Walter et al., 2020). Due to the frequent variation in composition between individuals, 
defining dysbiosis as such does not answer the question as to whether it is a cause or an 
effect. However, defining dysbiosis as a balance of commensals and pathogens holds 
promise due to the finding that species such as Streptococcus bovis, Bacteroides, and 
Clostridiaare are consistently found in CRC tissue while species such as Lactobacillus 
acidophilus and Bifidobacterium longum have been shown to inhibit tumorigenesis 
(Figure 5) (Cho et al., 2014; Saus et al., 2019). After a review of over 30 research articles 
with human CRC subjects, some researchers have concluded that a pro-carcinogenic 
dysbiosis is defined by an increase in Fusobacteria, Alistipes, Porphyromonadaceae, 
Coriobacteridae, Staphylococcaceae, Akkermansia spp. and Methanobacteriales and a 
decrease in Bifidobacterium, Lactobacillus, Ruminococcus, Faecalibacterium spp., 
Roseburia and Treponema (O’Keefe, 2016). Including a pro-carcinogenic arrangement in 
the definition is also supported by the emerging mechanisms of inflammation and altered 





Figure 5. Structure of Dysbiosis in CRC. CRC dysbiosis is identified by an increase in 
pathogens (+) and a decrease in commensals (-), with specific species associated with 
tissue and fecal samples. Pathogens may be inherently pathogenic or opportunistic. 
Modified from (Saus et al., 2019). 
 
 Along with many other bacterial species (Figure 6), the bacterial driver theory has 
consistently identified Streptococcus bovis (S. bovis), H. pylori, Bacteroides fragilis (B. 
fragilis), Enterococcus faecalis (E. faecalis), Clostridium septicum (C. septicum), 
Fusobacterium spp. and Escherichia coli (E. coli) as significant drivers of CRC (Baffy, 
2020; Gagnière et al., 2016; Watson et al., 2020). Of these, Fusobacterium nucleatum 
(Fn) has been the most consistently associated with CRC (Brennan & Garrett, 2019; 
Kostic et al., 2012). This theory is the most helpful in defining the mechanism by which 
the microbiome causes cancer because it focuses on the damage that occurs to the host 
rather than simply the presence of certain bacteria as in the dysbiosis theory. It is because 
of this that we can conclude that the microbiome promotes CRC by damaging DNA and 
activating cellular processes through inflammation, the production of genotoxins like 




Figure 6. Microbiota Associated with Colorectal Adenomas and Carcinomas. 
Watson et al. provides a thorough review of studies that associate microbiota with CRC 
at various taxonomical levels. These species commonly belong to 5 bacterial phyla and 
varies by adenoma (boxes in orange) and carcinoma (boxes in red). Taken from (Watson 





Figure 7. Mechanisms of Microbiome-mediated CRC. Microbiome-mediated CRC 
progresses through dysbiosis or through specific bacterial drivers. Through either 
mechanism, gut microbes damage host DNA and activate intracellular pathways through 
the production of toxins, inflammation, and altered metabolism. For the purposes of this 
review, oxidative stress is included under the discussion of inflammation. Modified from 













 Inflammation contributes to the initiation and progression of tumorigenesis 
through the action of pro-inflammatory cytokines such as TNF-α, IL-1, and IL-8 ( Cho et 
al., 2014). The significance of inflammation in driving CRC is evidenced by the well-
established risk of CRC in patients with IBD (Tomkovich et al., 2017). It has been 
proposed that these pro-inflammatory cytokines lead to DNA damage and the activation 
of intracellular pathways regulating cellular proliferation, apoptosis, and angiogenesis by 
binding to PRRs found on many cells. Reactive oxygen species (ROS) are one class of 
effectors molecules that damage nucleic acids, cellular proteins, and lipids, through the 
activity of their unstable, oxygen-containing free radicals (Belikov et al., 2015). Free 
radicals react with DNA and cause double-stranded DNA breaks, mutations, and 
crosslinks. Notable ROS include superoxide (O2•−), hydrogen peroxide (H2O2), hydroxyl 
radical (OH•), hypochlorous acid (HOCl), lipid peroxides (ROOH), singlet oxygen (1O2), 
and ozone (O3). They are commonly produced within the mitochondria of most cells 
during cellular respiration, but macrophages, T-lymphocytes, and dendritic cells can also 
be stimulated to increase ROS production in response to pro-inflammatory molecules 
such as nitric oxide, TNF-α, IL-1, IL-8, and prostaglandin-2 derivatives (Atzeni & Sarzi-
Puttini, 2013; Cho et al., 2014).  
 The microbiome contributes to ROS production, and therefore DNA damage, 
through the activation of the inflammasome pathway (Figure 8) (Gagnière et al., 2016; 
Morgillo et al., 2018). Pathogen associated molecular patterns (PAMPs) such as bacterial 
DNA and peptidoglycans, cross the intestinal barrier, travel to the liver, and bind TLRs 
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such as TLR9 and TLR4. This binding activates intracellular signaling pathways such as 
MAPK, NF-KB, and PI3K/AKT that ultimately lead to an increased expression of the 
pro-inflammatory molecules mentioned above. Species that proceed through this path 
include S. bovis, F. nucleatum, and E. faecalis, all of which have been consistently found 
in tissue and fecal samples of subjects with colorectal adenomas and carcinomas 
(Nakatsu et al., 2015; Wirbel et al., 2019). Lactobacillus, Enterococcus, 
and Streptococcus species have also been shown to produce ROS themselves (Strus et al., 
2009; Wakita et al., 2019). E. faecalis is unique in that it produces superoxide through the 
autoxidation of membrane-associated demethylmenaquinone (Huycke & Moore, 2002; 
Wang & Huycke, 2007). Other studies have identified bacteria of the genera 
Anaerostipes, Bilophila, Candidatus Arthromitus, Odoribacter, and Rikenella as potential 
sources of ROS (Wakita et al., 2019). 
 
Figure 8. Activation of Inflammasome Pathway by Microbiota in CRC. The 
inflammasome pathway is integral to the initiation and progression of many cancers, 
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including CRC. It begins with the passage of PAMPs across the intestinal epithelial 
barrier and the binding to the toll-like receptors TLR9 and TLR4. This binding activates a 
series of intracellular pathways that ultimately leads to the increased production of pro-
inflammatory cytokines. Some of these have been strongly associated with inducing CRC 
by promoting ROS production, increasing cellular proliferation, and inhibiting apoptosis. 
Taken from (Morgillo et al., 2018).  
 
 Pro-inflammatory cytokines also support tumor growth by activating cellular 
pathways that inhibit apoptosis, increase cellular proliferation, and promote angiogenesis 
(Cho et al., 2014; Gagnière et al., 2016). This occurs directly through the activation of 
intracellular pathways or indirectly through the action of effector molecules. 
Prostaglandin E2 (PGE2) is one major pro-inflammatory molecule that is produced in 
response to cytokine release (Sheng et al., 2020). Binding of pro-inflammatory cytokines 
to TLRs leads to the increased expression and activation of cyclooxygenase-2 (COX-2), a 
significant enzyme indicated in colorectal tumorigenesis. For example, COX-2 is a major 
source of PGE2 which has been shown to promote tumor growth and survival. PGE2 
inhibits apoptosis by decreasing the translocation of bax, a proapoptotic protein, to 
mitochondria and by activating the antiapoptotic proteins NF-κB and cAMP that act 
through an AKT-dependent mechanism (Tessner et al., 2004). This is done through the 
binding of EP2 (a class of G-protein coupled receptors) and the subsequent activation of 
PI3K which phosphorylates AKT. PGE2 increases cellular proliferation through a similar 
mechanism (Castellone et al., 2005). In this case, PGE2 also binds to EP2 and activates 
PI3K and AKT, but these events lead to the release of the B-catenin inhibitor, axin. B-
catenin is then free to regulate transcription factors that promote cellular proliferation. 
This finding is especially significant given the observation that mutations in APC/B-
catenin appear in a large percentage of CRCs. COX-2 also promotes tumor growth by 
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inducing angiogenesis. This occurs through the action of VEGF and b-FGF, two growth 
factors well-known to induce angiogenesis, instead of through PGE2 (Cho et al., 2014; 
Sheng et al., 2020).   
 The microbiome’s role in promoting tumorigenesis by inducing inflammation is 
supported at many levels. One important finding is that germ free, IL-10-deficient mice 
do not develop CRC when exposed to azoxymethane (AOM), a known carcinogen 
specific to CRC, whereas IL-10-deficient mice with conventional microbiota do (Neufert 
et al., 2007; Uronis et al., 2009). Moreover, certain species commonly implicated in 
human adenoma and carcinomas induce the expression of pro-inflammatory cytokines 
associated with tumorigenesis. For example, S. bovis induces the formation of IL-8 and 
TNF-α by endothelial cells, macrophages, and intestinal epithelial cells (Ellmerich et al., 
2000). This occurs through the binding of adhesins such as pil1, pil2, and pil3 or through 
the action of isolated antigens from the cell wall of S. bovis (Jans & Boleij, 2018). 
Additional support for the role of the microbiota in CRC includes the finding that 
Helicobacter japonicum induces the expression of inflammatory cytokines IFNγ, TNFα 
and IL17a, as well as iNOS (Shen et al., 2016). It is also possible that the microbiota 
promotes inflammation in mice with CRC by limiting the production of the anti-
inflammatory cytokine IL-10 by Tregs, though the exact mechanism is not clear (Dennis 
et al., 2013). Enterotoxigenic Bacteroides fragilis (ETBF) also promotes tumor growth 
through the production of IL-6 (Cho et al., 2014). ETBF induces the localization of IL-
17-producing CD4+ T cells (Th17) at the intestinal lamina propria in a STAT3-dependent 
manner, which induces other cells to produce IL-6 through NF-κB dependent pathways. 
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IL-6, STAT3, and NF-κB have all been consistently associated with inflammation-
mediated CRC (Cho et al., 2014). Interestingly, IM12, an isolate from the commensal 
Lactobacillus fermentum, was shown to reduce the expression of COX-2, the activation 
of NF-κB and STAT3, and the levels of IL-6, IL-17, and PGE2 (Lim et al., 2017). E. 
faecalis also induces infected-macrophages to increase the expression and activation of 
COX-2 (Wang & Huycke, 2016). COX-2 was shown to produce trans-4-hydroxy-2-
nonenal, a type of clastogen that is known to break double-stranded DNA, disrupt mitotic 
spindles and generate chromosomal instability. Strains of E. coli associated with human 
CRC were also shown to increase expression of COX-2 in a PKS-dependent manner 
(Raisch et al., 2015). Additionally, B-catenin activation occurs by the action of FadA 
adhesin F. nucleatum (Rubinstein et al., 2019). FadA binds E-cadherin and activates B-
catenin which leads to the modulation of transcription factors responsible for cell growth. 
However, F. nucleatum may promote CRC through inflammation-independent 
mechanisms given the finding that the binding of Fap2 to Gal-GalNAc leads to immune 
evasion and tumorigenesis (Abed et al., 2016; Tomkovich et al., 2017). Together, these 
findings support the theory that the loss of commensal bacteria or the introduction of 
harmful bacteria initiates colorectal carcinogenesis and its progression by promoting 
inflammation.  
BACTERIAL GENOTOXINS AND CRC 
 It has also been shown that bacterial genotoxins can induce CRC by damaging 
DNA, interfering with the G2/M cell cycle checkpoint, and inhibiting apoptosis. DNA 
damage leads to genomic instability by activating cancer genes or silencing tumor 
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suppressor genes. Damage may occur through chemical interactions with genetic material 
or indirectly through mediators like ROS. Tumor-like growth then occurs through the 
activation of various intracellular pathways. Altered cell cycles and the inhibition of 
apoptosis supports tumorigenesis, but these mechanisms have been less well-studied 
(Graillot et al., 2016). Cytolethal distending toxin (CDT) and colibactin, two major 
genotoxins belonging to the larger class of cyclomodulins, have been consistently 
identified in murine and human CRC samples. Other bacterial genotoxins include BFT, 
cytotoxic necrotizing factor, and cycle inhibiting factor, but these are not as strongly 
associated with CRC (Gagnière et al., 2016).  
 CDT is produced by many gram-negative bacteria such as Campylobacter 
species, Escherichia coli, Salmonella enterica serovar Typhi, Shigella dystenteriae, 
enterohepatic Helicobacter species, Actinobacillus actinomycetemcomitans, and 
Haemophilus ducreyi (Smith & Bayles, 2006). Of these, Helicobacter hepaticus, 
Helicobacter japonicum, multiple strains of E. coli, and Campylobacter jejuni have been 
consistently implicated in CRC tumorigenesis (Ge et al., 2017; Graillot et al., 2016; He et 
al., 2019; Seiwert et al., 2017; Shen et al., 2016; Shenker et al., 2016). In precancerous 
human colon epithelial cells, it was demonstrated that chronic exposure to CDT from E. 
coli led to malignant growth (Graillot et al., 2016). In APC and p53 deficient cells, 
however, malignant growth was independent of CDT exposure. CDT contributes to 
carcinogenesis through a variety of mechanisms, notably through damage to DNA. It 
does this through the action of its three subunits, CtdA, CtdB, and CtdC (Nešić et al., 
2004). The two lectin subunits (CdtA and CtdC) serve as potent virulence factors and as 
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regulatory units of the DNase1-like CdtB (Figure 9). When CdtB is released, it is free to 
translocate to the nucleus where it has been shown to induce double-stranded breaks 
(DSBs). One study found that these DSBs lead to an increase in PIP3 phosphatase 
activity, whereas another found an increase in both γH2AX, a phosphorylated histone and 
common measure of DNA damage, and 53BP1, tumor suppressor p53-binding protein 1 
(Graillot et al., 2016; Scuron et al., 2016; Seiwert et al., 2017; Shenker et al., 2016). All 
three of these responses have been involved in the progression of CRC. Further studies 
are needed to establish which of these methods contributes to CDT-mediated CRC. It is 
possible that these mechanisms may be species-specific, given the difference in species 
used to obtain CDT. It is also possible that the progression of CDT-mediated CRC is 
supported by inflammation as evidenced by the finding that pro-inflammatory IL-6 was 
decreased and anti-inflammatory IL-10 was increased in CDT-deficient mice (Ge et al., 
2017). Further studies are needed to identify the mechanisms by which CDT activates the 
host immune system. Other directions include the use of immunosuppressive drugs like 




Figure 9. Virulence of Cytolethal Distending Toxin. CDT is composed of three 
subunits, CdtA, CdtB, and CdtC. CdtA and CdtC mediate the adherence of the toxin to 
IEC and blocks the catalytic activity of CdtB. When CdtB is released, it forms double-
strand breaks in host DNA and reduces PIP3 phosphatase activity. As a result, pathways 
regulating IEC integrity, lymphocyte activity, and inflammation are activated. A 
combination of these three pathways results in further damage and ultimately the 
acquisition of cancer hallmarks. Taken from (Scuron et al., 2016). 
 
 Colibactin is produced by some strains of E. coli, Klebsiella pneumoniae, and 
other Enterobacteriaceae that contain polyketide synthetase (pks) genomic islands, or 
sections of bacterial genomes with evidence of vertical transmission (Bossuet-Greif et al., 
2018). Of these, pks+ E. coli have been found to be elevated in CRC patients and to 
induce tumor growth in mice (Arthur et al., 2012; Bossuet-Greif et al., 2018; Iyadorai et 
al., 2020; L. C.-H. Yu et al., 2018). The mechanisms by which this occurs includes 
damage to DNA, activation of cellular proliferation, and inhibition of apoptosis. One 
proposed mechanism of DNA-damage by colibactin occurs through the formation of 
inter-strand DNA cross-links after precolibactin is activated by deacylation (Bossuet-
Greif et al., 2018). However, this may not be sufficient to initiate CRC seeing that DNA 
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repair mechanisms involving ataxia-telangiectasia and Rad3-related kinase (ATR) and 
Fanconi anemia protein D2 (FANCD2) were also elevated in cells exposed to colibactin. 
Double-stranded breaks (DSBs) also occur in response to short-term exposure to 
colibactin in vitro and in vivo (Cuevas-Ramos et al., 2010). Alkylation of DNA with 
cyclopropane prevents replication and translation and is shown to occur through unstable 
intermediates produced by colibactin (Wilson et al., 2019). An increase in ROS 
production has also been observed with the introduction of colibactin, though this 
mechanism is not well understood (Gagnière et al., 2016). With these findings, one can 
conclude that colibactin damages DNA by inducing DSBs, inter-strand crosslinks, 
covalent bonds with acyl groups, and the production of ROS. Other effects of colibactin 
that promote CRC include increased cellular proliferation in mice through a CEACAM6-
dependent manner, though less literature covers this finding than that of colibactin-
mediated DNA damage (Raisch et al., 2014).  
BACTERIAL METABOLISM AND DEVELOPMENT OF CRC 
 The microbiome is necessary for the digestion of a variety of molecules ingested 
by the host so that they can be better absorbed. Specifically, it is needed for the digestion 
of select carbohydrates, vitamins, proteins, phytochemicals, and even some drugs 
(xenobiotic metabolism) (O’Keefe, 2016; Song & Chan, 2017). For example, gut 
commensals utilize fiber, a non-starch polysaccharide, as their primary energy source and 
produce short chain fatty acids (SCFA) such as acetate, propionate, and butyrate. 
Butyrate is especially important to the health of the host since it is the primary energy 
source of colonocytes as opposed to the usual glucose. It is formed through a complex, 
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multienzyme process with two major enzymes including butryl CoA-transferase and 
butyrate kinase (Figure 10). Together these three SCFAs, especially butyrate, promote 
anti-inflammatory and anti-tumorigenic effects (Bachmann et al., 2017; Chen & Vitetta, 
2018; Waldecker et al., 2008). This is accomplished through a combination of altering 
cellular proliferation, promoting apoptosis, inhibiting autophagy, and regulating the 
inflammasome pathway. For example, Butyrivibrio fibrisolvens is a bacterial species that 
is known to produce butyrate and was shown to halt autophagy of energy-starved cells in 
GF mice (W.-J. Lee & Hase, 2014). Acetate and propionate have been shown to promote 
IEC integrity by activating the inflammasome pathway upon binding GPR43 and 
GPR109A (Macia et al., 2015). It is important to note that some studies have observed 
increased cellular proliferation in response to butyrate while others have observed 
suppressed cellular proliferation. This is likely dose dependent, given the changing 
energy-needs of IEC. Some researchers have explained this as the ‘butyrate paradox’, 
where butyrate contributes to carcinogenesis by promoting cellular proliferation when 
cells are starved and suppresses carcinogenesis when energy-supply is in excess 
(O’Keefe, 2016). Lumenal SCFA concentrations of 80-130 mM have been identified as 
physiological ranges (W.-J. Lee & Hase, 2014). Other beneficial roles of the microbiota 
include the metabolism of vitamins which can be measured by the many enzymes they 
contain. Most of these enzymes participate in the MEP (2-methyl-D-erythritol 4-
phosphate) pathway and produce deoxyxylulose 5-phosphate (DXP) and isopenteryl 
pyrophosphate (IPP). DXP is a precursor for vitamin B1 (thiamine) and B6, and IPP is a 
precursor for membrane lipids, carotenoids, cholesterol, and over 25,000 other 
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derivatives (Tjalsma et al., 2012). However, the microbiota also contributes to 
carcinogenesis by producing molecules that are inherently harmful or harmful in a dose 
dependent fashion.  
 
Figure 10. Metabolic Pathways of Commensal Bacteria. Numerous bacteria have been 
implicated in the fermentation of carbohydrates and protein. SCFAs such as butyrate, 
acetate, and propionate have been consistently identified as beneficial to the host, with 
some studies identifying anti-inflammatory and anti-tumorigenic functions. Most of 
protein that is ingested as a part of one’s diet undergoes proteolysis and is absorbed in the 
small intestine. A small amount is converted into SCFAs, and the rest is fermented by 
microbiota in the large intestine. Some of these fermented products, especially N-nitroso 
compounds (NOCs), are carcinogenic and have been shown to induce CRC. This 
carcinogenic potential is dependent upon the activity of the microbiota but also the 
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concentration of supplied protein, the rate of detoxification of NOCs, and the rate of 
absorption by IECs. Taken from (O’Keefe, 2016). 
 
 When proteins reach the large intestine, most undergo proteolysis or fermentation 
and some are converted to SCFAs (Figure 10). Proteolysis is mediated by the microbiota 
and pancreatic enzymes to a lesser extent (trypsin, chymotrypsin, and elastase) and 
produces amino acids which are then be absorbed by the host (Yao et al., 2016). 
Fermentation is mediated entirely by the microbiota and produces gaseous products like 
ammonia, amines, nitrates, nitrites and hydrogen sulfide. When certain luminal 
concentrations of these products are reached, some can become carcinogenic (Knekt et 
al., 1999; Kobayashi, 2018; O’Keefe, 2016; Song & Chan, 2019). As early as 1988, 
researchers observed that high levels of ammonia induced colorectal adenocarcinomas in 
rats through a N-nitrosamine-dependent process (Clinton et al., 1988). N-nitrosamines are 
formed from the reaction of dietary nitrate or nitrites with amines, and their formation is 
dependent upon factors such as gastric acidity, transit time, diet, and gut flora activity and 
composition (Kobayashi, 2018). They damage DNA by forming alkyl-adducts such as 
O6-carboxymethylguanine (O6CMG) which are resistant to repair (Da Pieve et al., 2013; 
Lewin et al., 2006). E. coli, Proteus morganii, and Pseudomonas aeruginosa have been 
shown to produce carcinogenic N-nitrosamines and induce CRC, though this activity is 
also dependent upon oxygen content (Arese et al., 2003; Calmels et al., 1988). Since the 
carcinogenic potential of these fermented products are dose-dependent, it is reasonable to 
infer that their ability to initiate CRC also dependents upon the rate of production by 
microbiota, the rate of detoxification by the host, and the rate of absorption or excretion 
by the host (Yao et al., 2016).   
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 Colonic bacteria, primarily the anaerobic Clostridium clusters XIVa and XI and 
Eubacterium, also produce secondary bile salts which have been strongly associated with 
the development of adenomas and CRC (Song & Chan, 2019). Their production begins 
with the formation of primary bile acids from cholesterol in the liver and then their 
conversion into bile salts with the association of Na+ and K+ (Urdaneta & Casadesús, 
2017). Primary bile salts are then stored in the gallbladder and secreted into the 
duodenum when meals are consumed, especially those with high fat content. In humans, 
the major primary bile salts, cholate and chenodeoxycholate, are necessary for absorption 
of fatty acids. Of those that pass reabsorption in the small intestine, primary bile salts are 
converted to secondary bile salts by bacteria that contain 7-α dehydrogenase which 
removes the hydroxyl group at C7. Of the two major secondary bile salts, lithocholic acid 
and deoxycholic acid (DCA), DCA has a stronger association with CRC (O’Keefe, 2016; 
Song & Chan, 2019). For example, addition of 0.2% DCA, a dose significantly higher 
than physiological levels, for 8–10 months to the diet of 18 wild-type mice induced 
colonic tumors in 17 of 18 mice and cancer in 10 (Bernstein et al., 2011). Interestingly, 
this same study showed that the antioxidant chlorogenic acid could ameliorate DCA-
carcinogenesis. Bernstein et al. has proposed that DCA induces CRC by promoting the 
formation of ROS which damage DNA and alter cellular growth rates with the increased 
expression of NF-κB (Figure 11). This mechanism is supported by increased levels of 
fragmented DNA and the fluorescent ROS-probe (2',7'-dichlorodihydrofluorescein 
diacetate) in colon cancer cells exposed to DCA (Rastogi et al., 2010; Zeng et al., 2015). 
It is also supported by the finding that DCA increases the expression of NF-kB with the 
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activation of EGFR-MAPK pathway in response to intracellular calcium and CAMKII 
phosphorylation (Centuori et al., 2016; Centuori & Martinez, 2014). Other studies 
suggest that DCA may initiate tumor growth by antagonizing intestinal Farnesoid X 
receptor (FXR) function, though this mechanism has been less well-studied (Fu et al., 
2019) It is important to note that the presence of bacteria with DCA-producing abilities is 
necessary but insufficient to induce CRC. This is supported by evidence that diets high in 
omega 6 fatty acids also stimulated phosphatidylinositol-specific phospholipase C (PI-
PLC), mucosal PI-PLC, diacylglycerol (DAG) kinase, and protein kinase C (PKC) 




Figure 11. Mechanism by which Secondary Bile Salts Induce CRC. Secondary bile 
salts like DCA are produced by colonic bacteria and likely induce CRC through the 
action of ROS. DNA damage by ROS is often repaired by host mechanisms, but cells that 
resist repair survive and proliferate with the expression of NF-κB. NF-κB is regulated by 
many cellular pathways, including the EGFR-MAPK pathway. Recent evidence suggests 
that the EGFR-MAPK is activated by intracellular calcium and the phosphorylation of 




 There are many other metabolites produced by bacteria that induce CRC. One 
example is the formation of pro-carcinogenic methylazoxymethanol (MAM) from 
dimethylhydrazine (DMH) by colonic bacterial with β-glucuronidase (Cho et al., 2014). 
The mechanisms by which these molecules induce CRC are either reviewed elsewhere or 
remain undefined (Kim et al., 2018; W.-J. Lee & Hase, 2014; Sinha et al., 2016). Since 
metabolic activities of colonic bacteria are also dependent upon one’s diet, dietary 
changes show promise as a supplement to therapy. Many studies have established an 
increased risk of CRC with a Western diet (one that is high in red meat and fats and low 
in fiber) and a lower risk with a balanced diet (high in fiber from fruits and vegetables) 
(O’Keefe, 2016; Tan & Chen, 2016; Zmora et al., 2019). A recent clinical trial has taken 
advantage of these dietary findings to show that ω-3 fatty acid supplementation increases 
bacterial diversity which can then be used as a reliable predictor of lowered colonic 
PGE2, a proinflammatory molecule known to induce CRC (Djuric et al., 2019). The role 
of the diet in modulating the microbiota is also seen in the association of certain bacteria 
with obesity, though this has been debated and the mechanism has yet to be defined (Ley 
et al., 2005; Song & Chan, 2017; Stecher, 2015). Whatever the metabolite, it is clear that 
the colonization and activation of bacteria with pro-carcinogenic functions is one 









 It is theorized that humans and the microbiome evolved together so that the 
microbiota could benefit from a stable environment and humans could benefit from the 
functions of an expanded genome. With this review, it is becoming apparent that the two 
major physiological functions of the microbiome are maintaining intestinal immune 
homeostasis and metabolizing compounds from the host diet. Support for immune 
homeostasis is seen at many levels and is strengthened by the finding that germ free mice 
develop higher rates of colitis, hypersensitivity, and autoimmunity than conventionally 
raised mice. Support for dietary metabolism has been long established but has not been 
explained within the context of disease. Dysbiosis refers to the pathogenic process that 
results from the loss of commensals, acquisition of pathogens, or impaired function. 
Dysbiosis has been identified as a microbiome with increased Fusobacteria, Alistipes, 
Porphyromonadaceae, Coriobacteridae, Staphylococcaceae, Akkermansia spp. and 
Methanobacteriales and decreased Bifidobacterium, Lactobacillus, Ruminococcus, 
Faecalibacterium spp., Roseburia and Treponema. 
 The microbiome has also been associated with diseases including autism, 
cirrhosis, and obesity, but its association with CRC has the greatest supporting evidence. 
This relationship was first displayed through studies that found increased incidences of 
adenomas and carcinomas in germ free mice compared to conventionally raised mice. It 
was then strengthened by a series of in vitro and murine studies that identified specific 
species that can induce colonic adenomas and carcinomas. Streptococcus bovis (S. bovis), 
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H. pylori, Bacteroides fragilis (B. fragilis), Enterococcus faecalis (E. faecalis), 
Clostridium septicum (C. septicum), Fusobacterium spp. and Escherichia coli (E. coli) 
have been consistently identified as significant drivers of CRC. However, a major 
obstacle in establishing the microbiome as a causative agent instead of an effect of host 
processes was the lack of identification of molecular mechanisms. Other papers have 
reviewed aspects of these mechanisms, but none have reviewed them together or to this 
depth.  
 After a review of current literature, it is apparent that certain microbes induce 
CRC by deranging intestinal immune homeostasis, producing genotoxins, and 
metabolizing molecules sourced by the host into carcinogens. Under normal conditions, 
the microbiome is necessary to prevent the colonization of pathogens, promote intestinal 
barrier integrity, induce the development of immune cells and tissues, and to modulate 
their function. Many of these activities are mediated by the production of cytokines, 
AMPs, and IgA in response to microbiota. The microbiota has also been shown to induce 
the formation of the mucus layer and alter tight junctions that connect IECs. When these 
functions are impaired, intestinal inflammation is triggered. Inflammation is mediated by 
the activity of pro-inflammatory cytokines (especially TNF-α, IL-1, IL-6, and IL-8) 
which induce the formation of ROS and the expression of COX-2. These molecules have 
been consistently associated with CRC and various members of the microbiome induce 
their activity. Activation of the inflammasome pathway and the subsequent production of 
NF-κB is central to this process.   
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 The microbiota also induces CRC through the production of toxins that directly 
damage DNA. CDT and colibactin are two major genotoxins produced by the microbiota 
that have been associated with CRC. This review confirms this association with the 
findings that CDT induces DNA damage through the activity of its catalytic subunit, 
CdtB. By this mechanism, damage commonly occurs in DNA that results in increased 
activity of PIP3 phosphatase. Colibactin induces CRC by forming double-stranded breaks 
(DSBs), inter-strand crosslinks, covalent bonds with acyl groups, and promoting the 
formation of ROS. These events then lead to an increase in cellular proliferation and the 
inhibition of apoptosis.  
 The final mechanism by which the microbiome induces CRC includes the 
production of carcinogens from molecules supplied by the host. SCFAs have been shown 
to paradoxically increase and decrease cellular proliferation, but it is likely that its 
activity is dose dependent. Butyrate is one SCFA that is significant in promoting anti-
inflammatory and anti-tumorigenic effects. Protein fermentation by microbiota can be 
beneficial to the host, but also produces carcinogens such as ammonia, amines, nitrates, 
nitrites and hydrogen sulfide. The reaction of nitrates and nitrites with amines leads to the 
formation of N-nitrosomines which damage DNA by forming alkylated adducts. 
Secondary bile salt formation is a metabolic process of the microbiota and is largely 
carcinogenic. In humans, DCA induces CRC by promoting the formation of ROS which 
damage sections of DNA that regulate NF-κB expression. In this model, NF-κB 
expression is possibly stimulated by the activation of the EGFR-MAPK pathway in 
response to intracellular calcium and CAMKII phosphorylation.  
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 With these identified mechanisms, the causative role of the microbiome in 
colorectal carcinogenesis is becoming clearer. Studies that confirm these findings are 
needed to definitively reach this conclusion. Until then, studies that investigate 
microbiota-targeted CRC therapies will provide additional support. Promise is seen in 
studies that target the activity of microbiota like the use of phenylalanine ammonia lyase 
as an effective CRC therapy in mice by inhibiting proliferation and inducing apoptosis of 
tumor cells (J. Yang et al., 2019). Others have identified probiotics that modulate 
histamine production as a potential CRC therapy due to their ability to reduce colorectal 
tumor size and production of pro-carcinogenic myeloid cells (Gao et al., 2017). Using 
biomarkers from the microbiome has also successfully identified CRC with greater 
accuracy and earlier in development (Liang et al., 2017; Mangifesta et al., 2018; J. Yu et 
al., 2017). It is my hope that this review of mechanisms may provide researchers with 
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